Increasing pharmaceutical copayments: Impact on asthma medication utilization and outcomes

American Journal of Managed Care

Volumn 17, Issue 10, 2011, Pages 703-710

  Campbell, Jonathan D ^a   Allen Ramey, Felicia ^b   Sajjan, Shiva G ^b   Maiese, Eric M ^b   Sullivan, Sean D ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; ASTHMA; CONTROLLED STUDY; DRUG COST; DRUG UTILIZATION; EMERGENCY WARD; FEMALE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; COHORT STUDIES; DEDUCTIBLES AND COINSURANCE; EMERGENCY SERVICE, HOSPITAL; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE, HEALTH; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRESCRIPTION FEES; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 80054770306     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Dor A, Encinosa W. How does cost-sharing affect drug purchases? insurance regimes in the private market for prescription drugs. J Econ Manage Strategy. 2010;19:545-574.
2. Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care. 2005;11(11):730-740. (Pubitemid 41608213)
3. Remler DK, Greene J. Cost-sharing: a blunt instrument. Annu Rev Public Health. 2009;30:293-311.
4. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344-2350. (Pubitemid 38656301)
5. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescriptiondrug utilization and spending. N Engl J Med. 2003;349(23):2224-2232. (Pubitemid 37485139)
6. Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs. JAMA. 2002;288(14):1733-1739.
7. Dormuth CR, Glynn RJ, Neumann P, Maclure M, Brookhart AM, Schneeweiss S. Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma. Clin Ther. 2006;28(6):964-978; discussion 962-963.
8. Kozyrskyj AL, Mustard CA, Cheang MS, Simons FE. Income-based drug benefit policy: impact on receipt of inhaled corticosteroid prescriptions by Manitoba children with asthma. CMAJ. 2001;165(7):897-902. (Pubitemid 34028227)
9. Fung V, Tager IB, Brand R, Newhouse JP, Hsu J. The impact of generic- only drug benefits on patients' use of inhaled corticosteroids in a Medicare population with asthma. BMC Health Serv Res. 2008;8:151.
10. Crown WH, Berndt ER, Baser O, et al. Benefit plan design and prescription drug utilization among asthmatics: do patient copayments matter? Front Health Policy Res. 2004;7:95-127.
11. Thomson Reuters. MarketScan Database Description. http://thomsonreuters. com/products-services/healthcare/healthcare-products/ Pharmaceuticals/mktscan- res-db. Accessed September 1, 2010.
12. HEDIS. NDC 2009. http://www.ncqa.org/tabid/892/Default.aspx. Accessed June 1, 2010.
13. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health. 2009;12(6):989-995.
14. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139. (Pubitemid 41587600)
15. Gilberg K, Laouri M, Wade S, Isonaka S. Analysis of medication use patterns: apparent overuse of antibiotics and underuse of prescription drugs for asthma, depression, and CHF. J Manag Care Pharm. 2003;9(3):232-237.
16. Bahadori K, Doyle-Waters MM, Marra C, et al. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24.
17. Navaratnam P, Friedman H, Urdaneta E. The impact of adherence and disease control on resource use and charges in patients with mild asthma managed on inhaled corticosteroid agents. Patient Prefer Adherence. 2010;4:197-205.
18. Campbell JD, Blough DK, Sullivan SD. Comparison of guidelinebased control definitions and associations with outcomes in severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol. 2008;101(5): 474-481.
19. Sullivan SD, Rasouliyan L, Russo PA, Kamath T, Chipps BE. Extent, patterns, and burden of uncontrolled disease in severe or difficult-totreat asthma. Allergy. 2007;62(2):126-133. (Pubitemid 46090293)
20. Choudhry NK, Rosenthal MB, Milstein A. Assessing the evidence for value-based insurance design. Health Aff (Millwood). 2010;29(11):1988-1994.
21. Bae SJ, Paltiel AD, Fuhlbrigge AL, Weiss ST, Kuntz KM. Modeling the potential impact of a prescription drug copayment increase on the adult asthmatic Medicaid population. Value Health. 2008;11(1):110-118. (Pubitemid 351160881)
22. Ungar WJ, Paterson JM, Gomes T, et al. Relationship of asthma management, socioeconomic status, and medication insurance characteristics to exacerbation frequency in children with asthma. Ann Allergy Asthma Immunol. 2011;106(1):17-23.
23. Carlton RI, Bramley TJ, Nightengale B, Conner TM, Zacker C. Review of outcomes associated with formulary restrictions: focus on step therapy. Am J Pharm Benefits. 2010;2(1):50-58.